DC
ZVRA icon

Diametric Capital’s Zevra Therapeutics ZVRA Stock Holding History

Diametric Capital’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Buy
231,465
+123,441
+114% +$1.37M 0.35% 41
2026
Q1 		$1.01M Buy
+108,024
New +$974K 0.26% 96

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Diametric Capital's ZVRA Position: Q2 2026 in Review

Diametric Capital increased its Zevra Therapeutics (ZVRA) stake by 114% in Q2 2026, buying an estimated $1.37M and bringing the position to 231,465 shares worth $3.32M. The position accounts for 0.35% of the portfolio, ranked #41.

Diametric Capital first reported a position in ZVRA in Q1 2026 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Diametric Capital held 231,465 shares of Zevra Therapeutics worth $3.32M as of Q2 2026.
  • Diametric Capital bought 123,441 Zevra Therapeutics shares in Q2 2026, an estimated $1.37M.
  • Zevra Therapeutics made up 0.35% of Diametric Capital's portfolio in Q2 2026, its #41 holding.
  • Diametric Capital first reported a position in Zevra Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.